FDA requires GLP-1 warnings about rare permanent vision loss
The FDA is requiring GLP-1 medicines, including Ozempic, Wegovy, Mounjaro and Zepbound, to carry warnings about non-arteritic anterior ischemic optic neuropathy, or NAION. The condition damages the optic nerve when its blood supply is restricted, potentially causing abrupt, permanent vision loss. [4][8] The agency's studies produced mixed results, supporting a warning about a potential risk rather than a settled causal relationship. [8]
People taking these medicines for diabetes or weight management face a new treatment consideration: an uncommon eye complication can have permanent consequences. The FDA advises clinicians to consider discontinuing a GLP-1 drug in patients who develop NAION unless treatment benefits clearly outweigh the risk—not to stop treatment in every patient. [8]
Key insights
- NAION occurs in roughly two to 10 people per 100,000 in the general population; that background figure is not an estimate of the extra risk from GLP-1 treatment. [8]
- Across 126 trials involving more than 130,000 patients, the FDA identified 15 probable cases: 10 among GLP-1 recipients and five among placebo recipients. Those counts alone do not establish a relative risk without the treatment-group denominators. [8]
- A separate FDA study found no increased risk compared with SGLT-2 diabetes drugs, but an increase compared with DPP-4 drugs; diabetes and cardiovascular conditions also overlap with NAION risk factors. [8]